Determination of pulmonary irritant threshold concentrations of hexamethylene-1,6-diisocyanate (HDI) prepolymers by bronchoalveolar lavage in acute rat inhalation studies according to TRGS 430.
Pulmonary irritant threshold concentrations of two hexamethylene-1,6-diisocyanate (HDI)-based prepolymers (I: polymeric emulsfier modified and II: oligomeric allophanate modified) were determined in acute inhalation studies according to TRGS 430 (Dangerous Substances Technical Rule, isocyanates, Germany), based on benchmark extrapolation of bronchoalveolar lavage fluid (BALF) total protein. It was also investigated if the method is robust enough to be transferred to an independent laboratory. Five male Wistar rats per group were exposed nose-only to the test substances as liquid aerosols to concentrations of 0, 0.5, 3, 15 mg/m(3) for both test substances with an additional test group at 50 mg/m(3) for test substance I. The duration of the exposure was 6h, followed by serial sacrifices 1 day, 3 days and 7 days post exposure. BALF was analyzed for biochemical and cytological markers indicative for injury of the bronchoalveolar region. The exposure of rats to test substance I and II caused dose depended lung irritation with BALF total protein concentration being the most sensitive indicator of pulmonary effects. The extrapolated no observed adverse effect level of test substance I was 1.1 mg/m(3) and that of test substance II 2.3 mg/m(3). The acute pulmonary irritant threshold concentrations were found to be similar to those reported by [Pauluhn, J., 2004. Pulmonary irritant potency of polyisocyanate aerosols in rats: comparative assessment of irritant threshold concentrations by bronchoalveolar lavage. J. Appl. Toxicol. 24, 231-247] for HDI-homopolymers and other HDI-based polyisocyanates, and were at least 30 times higher than the MAK (occupational exposure limit) value for the HDI monomer (0.035 mg/m(3)). Thus the EBW (exposure assessment value) for these two HDI-based prepolymers can be established at 10x MAK, i.e. at 0.35 mg/m(3).
Ma-Hock
L
L
BASF Aktiengesellschaft, Experimental Toxicology and Ecology, Z 470, D-67056 Ludwigshafen, Germany.
Gamer
A O
AO
Deckardt
K
K
Leibold
E
E
van Ravenzwaay
B
B
D000280:Administration, Inhalation; D000336:Aerosols; D000393:Air Pollutants / Q000633:toxicity*; D000397:Air Pollution / Q000331:legislation & jurisprudence; D000818:Animals; D001681:Biological Assay; D018893:Bronchoalveolar Lavage; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry*; D003485:Cyanates / Q000008:administration & dosage / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005858:Germany; D006813:Humidity; D019570:Inhalation Exposure / Q000331:legislation & jurisprudence; D017953:Isocyanates; D008168:Lung / Q000187:drug effects*; D008297:Male; D019055:No-Observed-Adverse-Effect Level; D016273:Occupational Exposure / Q000331:legislation & jurisprudence*; D051381:Rats; D017208:Rats, Wistar; D013696:Temperature; D023382:Toxicity Tests, Acute
D000336:Aerosols; D000393:Air Pollutants; D003485:Cyanates; D017953:Isocyanates; C015262:1,6-hexamethylene diisocyanate